Objective To assess the safety and efficacy of novel pulsed field ablation (PFA) as a treatment option for atrial fibrillation. Methods and results We searched PubMed, Ovid, Google Scholar, Web of Science, and Scopus databases and several major scientific conferences for studies reporting results regarding PFA. A total of 16 studies were included, reporting 485 patients with atrial fibrillation who underwent pulsed field operations. Patients averaged 60 years of age. The total duration of the procedure is 94 min. The average Fluoro procedure takes 17 min. Isolation of all pulmonary veins was 100% with a 95% confidence interval (p > 0.05). Overall, the recurrence rate of arrhythmia in the participants was 2.84% (95%-CI) (p > 0.05). Complications were detected during or after PFA surgery at a rate of 2.23% (p< 0.05) with 95%-CI indicating high safety of the PFA procedure. Conclusion Using pulsed-field ablation as a new treatment for atrial fibrillation has proven to be safe and effective.

Most instances of Guillain-Barré syndrome (GBS) are caused by immunological stimulation and are discovered after vaccinations for tetanus toxoid, oral polio, and swine influenza. This systematic study investigated GBS cases reported after receiving the COVID-19 vaccination.

Here we report a patient with 2q37 deletion syndrome confirmed by comparative genomic hybridization (CGH) plus single nucleotide polymorphism (SNP), who does not suffer from mental developmental abnormalities. The patient, however, does suffer from fatigue and gross motor delay, and the presence of a patent foramen ovale.